ALNYLAM PHARMACEUTICALS INC holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 3,351,762 | $905,042,775 | 0.52% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 14, 2025 |
| June 30, 2025 | 3,197,096 | $1,042,541,035 | 0.59% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 13, 2025 |
| Sept. 30, 2025 | 2,321,230 | $1,058,480,880 | 0.57% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Nov. 13, 2025 |
| Dec. 31, 2025 | 1,964,415 | $781,149,625 | 0.42% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 13, 2026 |
| March 31, 2026 | 1,929,253 | $638,331,940 | 0.35% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 14, 2026 |
| June 30, 2026 | 1,955,393 | $588,631,955 | 0.31% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 13, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.